Preclinical Development of EDIT-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment

Christopher M. Borges, Kevin Wasko, Jared M. Nasser, Kelly Donahue, Amanda Pfautz, Lincy Prem Antony, Glenn Leary, Steven Sexton, Richard A. Morgan, and Karrie K. Wong

Editas Medicine, Cambridge, MA
Disclosures

Employees and shareholders of Editas Medicine:
EDIT-201 has been engineered to enhance the anti-tumor function of NK cells

Objective:
To evaluate the in vitro anti-tumor activity of EDIT-201, an NK cell therapy derived from healthy human donor NK cells with enhanced effector function through Cas12a knockout of CISH and TGFBR2

Advantages of NK cells
- Recognize broad array of tumor ligands
- Recognize malignant cells that lack MHC I
- Rapid degranulation leads to robust tumor cytotoxicity
- Recruit and engage cells of the adaptive immune system to enhance tumor cytotoxicity

CISH: cytokine-inducible SH2-containing protein gene; IL: interleukin; KO: knockout; MHC: major histocompatibility complex; NK: natural killer; TGF-β: tumor growth factor beta; TGFBR2: TGF-β receptor II gene
EDIT-201 demonstrated enhanced anti-tumor activity against Nalm6 cells (B cell leukemia cell line) in the presence of TGF-β.

Representative data of 5 unique donors and 2 independent experiments.
Serial-killing activity of NK cells can be measured by challenging NK cells with a bolus of Nalm6 cells every 48 hours for up to 20 days
EDIT-201 demonstrated sustained serial killing of Nalm6 cells for >8 days in the presence of TGF-β

Representative data of 6 unique donors and 2 independent experiments
EDIT-201 produced increased levels of inflammatory cytokines throughout the serial-killing assay in the presence of TGF-β.

Supernatants from Nalm6 serial-killing assay (representative data of 3 unique PBMC donors)

**Increased IFN-γ**

- **Unedited NK cells**
- **EDIT-201**

**Increased TNF-α**

- **Unedited NK cells**
- **EDIT-201**

IFN: interferon; PBMC: peripheral blood mononuclear cell
EDIT-201 demonstrated sustained serial-killing activity against numerous hematologic tumor cell lines in the presence of TGF-β

- **Sustained cytotoxicity against Raji cells (Burkitt’s lymphoma)**
- **Sustained cytotoxicity against RPMI8226 cells (multiple myeloma)**
- **Sustained cytotoxicity against THP-1 cells (acute monocytic leukemia)**

Representative data of minimum 5 unique donors and 5 independent experiments
Conclusions

EDIT-201 is being developed as a **healthy donor-derived NK cell therapy** with CRISPR-Cas12a-mediated editing at **CISH and TGFBR2 loci**

EDIT-201 demonstrated **sustained anti-tumor serial-killing activity** in the presence of the potent immunosuppressive cytokine TGF-β across various hematologic cell lines *in vitro*, suggesting that EDIT-201 is a potent and versatile cell-based medicine

EDIT-201 is being advanced to **clinical development** as an allogeneic cell-based medicine for solid tumors
Acknowledgments

- The authors would like to thank all of their Editas colleagues for helping to plan, perform, analyze, and present this work.
- Editorial assistance was provided by Bethany Garnett of 2 the Nth (Cheshire, UK).
- This work was funded by Editas Medicine.